Alzheimer Disease Clinical Trial
Official title:
Effects of Strength Exercise on Fall Risk in Elderly With Alzheimer's Disease
Verified date | March 2022 |
Source | University of Jaén |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Interventional study to show the effects of strength exercise on fall risk in elderly with Alzheimer's disease
Status | Completed |
Enrollment | 64 |
Est. completion date | March 4, 2022 |
Est. primary completion date | December 10, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: - accept to participate in the study, through informed consent - subjects aged 60 or over with medical diagnosis of AzlheimerĀ“s disease - minimal physical and mental state to perform the cognitive tests and strength exercise routine Exclusion Criteria: - Neurodegenerative disease other than Alzheimer's disease - Suffering from serious somatic or psychiatric illnesses - Patients who have practiced strength exercise regularly |
Country | Name | City | State |
---|---|---|---|
Spain | Alexander achalandabaso | Alcalá De Henares | Madrid |
Spain | A.F.A La Estrella | Jaén | Andalucía |
Lead Sponsor | Collaborator |
---|---|
University of Jaén |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline Short physical performance battery (SPPB) at 3 and 6 months | Informs about fall risk and mobility Score: 0-12 High score means better result | Baseline, 3 and 6 months (3 months after intervention) | |
Secondary | Change from baseline Activities specific balance confidence scale (ABC scale) at 3 and 6 months | This questionnaire allows to measure the balance of a person Score: 0-100% High percentage means better result | Baseline, 3 and 6 months (3 months after intervention) | |
Secondary | Change from baseline Lawton Instrumental Activities of Daily Living Scale (IADL) at 3 and 6 months | This tool gives us information about performance in activities of daily living Score: 0-8 High score means better result | Baseline, 3 and 6 months (3 months after intervention) | |
Secondary | Change from baseline Quality of life Alzheimer Disease (QoL-AD) at 3 and 6 months | Through this test we can know the level of quality of life of users who suffer from this disease Score: 0-52 High score means better result | Baseline, 3 and 6 months (3 months after intervention) | |
Secondary | Change from baseline FRAIL test at 3 and 6 months | This rapid test allows to determine the state of frailty of older people Score: 0-5 High score means worst result | Baseline, 3 and 6 months (3 months after intervention) | |
Secondary | Change from baseline Mini Mental State Examination (MMSE) at 3 and 6 months | This test gives us information about the cognitive performance of the participants Score: 0-30 High score means better result | Baseline, 3 and 6 months (3 months after intervention) | |
Secondary | Change from baseline Neuropsychiatric Inventory (NPI-Q) at 3 and 6 months | This tool allows to specify the neuropsychiatric symptoms patients present Score: 0-36 High score means worst result | Baseline, 3 and 6 months (3 months after intervention) | |
Secondary | Change from baseline Manual dynamometry at 1,2,3 and 6 months | This test allows to quantify force an individual presents in a simple way Score: 0-8 High score means better result | Baseline, 1, 2, 3 and 6 months (3 months after intervention) | |
Secondary | Modified Borg scale | In this way we can measure the level of perceived exertion during the intervention with strength exercise Score: 0-10 High score means more fatigue | 3 times/week during strength exercises sessions | |
Secondary | Change from baseline One Maximum repetition strength test (1 MR) at 1,2,3 and 6 months | Allows you easily to assess maximum strength Score: 0-8 High score means more strength level | Baseline, 1 , 2 , 3 and 6 months (3 months after intervention) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |